SlideShare a Scribd company logo
GlaxoSmithKline
Pharmaceutical
Submitted To,
Prof. Ramesh .S
Type             Public limited company
                 LSE:
Traded as
                 NYSE:

Industry         Pharmaceutical, biotechnology

                 Glaxo Wellcome
Predecessor(s)
                 SmithKline Beecham
Founded          2000 (London)
Headquarters     London, United Kingdom

                 Chris Gent (Chairman)
Key people
                 Andrew Witty (Chief Executive)


                 Pharmaceuticals, vaccines, oral healthcare
Products         products, nutritional products, over-the-counter
                 medicines

Revenue          £28.392 billion (2010)[1]


Net income       £1.853 billion (2010)[1]


Total equity     £9.745 billion (2010)[2]
Employees        96,500 (2010
Compound Annual Growth
Rate - CAGR
 The year-over-year growth rate of an
  investment over a specified period of
  time.
 Formula for CAGR


    [{Current value of sales/value of sales
    from base year]1/n -1}* 100]
GLAXOSMITHKLINE
PHARMACEUTICALS (CAGR)
  Year     2010       2009       2008       2007       2006
Net Sales 2,125.20   1,884.14   1,676.36   1,578.58   1,541.93
  PAT      563.69    512.29     576.57     537.66     545.51
 CAGR      8.35%      5.14%      2.11%      0.59%
 (Sales)
 CAGR      0.82%     -1.56%      1.39%     -0.36%
 (PAT)
10.00%




 8.00%




 6.00%




 4.00%
                                     CAGR (Sales)
                                     CAGR (PAT)
 2.00%




 0.00%
         2010   2009   2008   2007


-2.00%




-4.00%
CAGR of Industry (Sales)
  Year      2010       2009       2008       2007       2006
RANBAXY    5,646.37   4,781.59   4,652.04   4,293.02   4,165.12
 LUPIN LTD 3,690.09   2,954.70   2,575.39   1,985.79   1,652.93
DR.REDDY'S
           4,395.60   3,999.50   3,343.89   3,783.26   2,003.26
   LAB
  Glaxos
           2,125.20   1,884.14   1,676.36   1,578.58   1,541.93
   mith
  Total    15857.26   13619.93   12247.66   11640.65   9363.24
 CAGR      14.08%      9.82%      6.94%      5.59%
CAGR of Industry (PAT)
  Year       2010       2009       2008       2007       2006
RANBAXY     1,148.73   571.98    -1,044.80   617.72     380.54
LUPIN LTD   648.93     416.97     443.38     302.06     182.72
DR.REDD
            846.10     560.90     475.22     1,176.86
 Y'S LAB                                                211.12
Glaxos
            563.69     512.29     576.57     537.66     545.51
 mith
 TOTAL      3207.45    2062.14    450.37      2634.3    1319.89
 CAGR       24.85%     11.80%    -23.57%     18.86%
Industry Vs. Glaxosmith
  YEAR              2010          2009       2008       2007

Glaxosmith      8.35%             5.14%      2.11%     0.59%

 Industry
               14.08%             9.82%      6.94%     5.59%
   16.00%

   14.00%

   12.00%

   10.00%

    8.00%                                             Glaxosmith
    6.00%                                             Industry

    4.00%

    2.00%

    0.00%
             2010          2009       2008     2007
Thank You

More Related Content

Similar to CAGR Compound Annual Growth Rate

Khimpharm
KhimpharmKhimpharm
Khimpharm
Makha U
 
Pharma marketing
Pharma marketingPharma marketing
Pharma marketing
Uzair Ahmed
 
Strategic Management Assignment Presentation on Competitor Analysis in Pharma...
Strategic Management Assignment Presentation on Competitor Analysis in Pharma...Strategic Management Assignment Presentation on Competitor Analysis in Pharma...
Strategic Management Assignment Presentation on Competitor Analysis in Pharma...
WaliaFatima3
 
GSk financial statement analysis
GSk financial statement analysisGSk financial statement analysis
GSk financial statement analysis
Nguyen Thi Trang Nhung
 
Equities Project Presentation To Investors
Equities Project Presentation To InvestorsEquities Project Presentation To Investors
Equities Project Presentation To Investors
levitsa101
 
4Q06 Conference Call Presentation
4Q06 Conference Call Presentation4Q06 Conference Call Presentation
4Q06 Conference Call PresentationPDG Realty
 
Walid saafan pharma_experience
Walid saafan pharma_experienceWalid saafan pharma_experience
Walid saafan pharma_experience
Walid Saafan
 
Mid cap & small cap performance
Mid cap & small cap performanceMid cap & small cap performance
Mid cap & small cap performance
BFSICM
 
Healthcare Sector Update - October 2015
Healthcare Sector Update - October 2015Healthcare Sector Update - October 2015
Healthcare Sector Update - October 2015
Duff & Phelps
 
Overall demand environment remains soft in the Consumer Sector in Q4
Overall demand environment remains soft in the Consumer Sector in Q4Overall demand environment remains soft in the Consumer Sector in Q4
Overall demand environment remains soft in the Consumer Sector in Q4
IndiaNotes.com
 
Dividend weekly 03 2013
Dividend weekly 03 2013Dividend weekly 03 2013
Dividend weekly 03 2013
Dividend Yield
 
Daily Newsletter for 10th November, 2010
Daily Newsletter for 10th November, 2010Daily Newsletter for 10th November, 2010
Daily Newsletter for 10th November, 2010Fullerton Securities
 
Evolução dos valores programados - meio tv - Governo Federal
Evolução dos valores programados - meio tv -  Governo FederalEvolução dos valores programados - meio tv -  Governo Federal
Evolução dos valores programados - meio tv - Governo Federal
Ivson Alves
 
Final presentation
Final presentationFinal presentation
Final presentationZe Shao
 
Healthcare Sector Update - November 2015
Healthcare Sector Update - November 2015Healthcare Sector Update - November 2015
Healthcare Sector Update - November 2015
Duff & Phelps
 
Pharma industries _bhavik s amin
Pharma industries  _bhavik s aminPharma industries  _bhavik s amin
Pharma industries _bhavik s aminBhavik Amin
 

Similar to CAGR Compound Annual Growth Rate (20)

Glaxo Result Update
Glaxo Result UpdateGlaxo Result Update
Glaxo Result Update
 
Khimpharm
KhimpharmKhimpharm
Khimpharm
 
Pharma marketing
Pharma marketingPharma marketing
Pharma marketing
 
Strategic Management Assignment Presentation on Competitor Analysis in Pharma...
Strategic Management Assignment Presentation on Competitor Analysis in Pharma...Strategic Management Assignment Presentation on Competitor Analysis in Pharma...
Strategic Management Assignment Presentation on Competitor Analysis in Pharma...
 
Etizola brand plan
Etizola brand planEtizola brand plan
Etizola brand plan
 
GSk financial statement analysis
GSk financial statement analysisGSk financial statement analysis
GSk financial statement analysis
 
Equities Project Presentation To Investors
Equities Project Presentation To InvestorsEquities Project Presentation To Investors
Equities Project Presentation To Investors
 
4Q06 Conference Call Presentation
4Q06 Conference Call Presentation4Q06 Conference Call Presentation
4Q06 Conference Call Presentation
 
Walid saafan pharma_experience
Walid saafan pharma_experienceWalid saafan pharma_experience
Walid saafan pharma_experience
 
Mid cap & small cap performance
Mid cap & small cap performanceMid cap & small cap performance
Mid cap & small cap performance
 
Healthcare Sector Update - October 2015
Healthcare Sector Update - October 2015Healthcare Sector Update - October 2015
Healthcare Sector Update - October 2015
 
Overall demand environment remains soft in the Consumer Sector in Q4
Overall demand environment remains soft in the Consumer Sector in Q4Overall demand environment remains soft in the Consumer Sector in Q4
Overall demand environment remains soft in the Consumer Sector in Q4
 
Dividend weekly 03 2013
Dividend weekly 03 2013Dividend weekly 03 2013
Dividend weekly 03 2013
 
Daily Newsletter for 10th November, 2010
Daily Newsletter for 10th November, 2010Daily Newsletter for 10th November, 2010
Daily Newsletter for 10th November, 2010
 
Evolução dos valores programados - meio tv - Governo Federal
Evolução dos valores programados - meio tv -  Governo FederalEvolução dos valores programados - meio tv -  Governo Federal
Evolução dos valores programados - meio tv - Governo Federal
 
Final presentation
Final presentationFinal presentation
Final presentation
 
Healthcare Sector Update - November 2015
Healthcare Sector Update - November 2015Healthcare Sector Update - November 2015
Healthcare Sector Update - November 2015
 
closing nov
closing novclosing nov
closing nov
 
Pharma industries _bhavik s amin
Pharma industries  _bhavik s aminPharma industries  _bhavik s amin
Pharma industries _bhavik s amin
 
Dose Flux Competition
Dose Flux CompetitionDose Flux Competition
Dose Flux Competition
 

Recently uploaded

The European Unemployment Puzzle: implications from population aging
The European Unemployment Puzzle: implications from population agingThe European Unemployment Puzzle: implications from population aging
The European Unemployment Puzzle: implications from population aging
GRAPE
 
Scope Of Macroeconomics introduction and basic theories
Scope Of Macroeconomics introduction and basic theoriesScope Of Macroeconomics introduction and basic theories
Scope Of Macroeconomics introduction and basic theories
nomankalyar153
 
How to get verified on Coinbase Account?_.docx
How to get verified on Coinbase Account?_.docxHow to get verified on Coinbase Account?_.docx
How to get verified on Coinbase Account?_.docx
Buy bitget
 
This assessment plan proposal is to outline a structured approach to evaluati...
This assessment plan proposal is to outline a structured approach to evaluati...This assessment plan proposal is to outline a structured approach to evaluati...
This assessment plan proposal is to outline a structured approach to evaluati...
lamluanvan.net Viết thuê luận văn
 
when will pi network coin be available on crypto exchange.
when will pi network coin be available on crypto exchange.when will pi network coin be available on crypto exchange.
when will pi network coin be available on crypto exchange.
DOT TECH
 
can I really make money with pi network.
can I really make money with pi network.can I really make money with pi network.
can I really make money with pi network.
DOT TECH
 
一比一原版(GWU,GW毕业证)加利福尼亚大学|尔湾分校毕业证如何办理
一比一原版(GWU,GW毕业证)加利福尼亚大学|尔湾分校毕业证如何办理一比一原版(GWU,GW毕业证)加利福尼亚大学|尔湾分校毕业证如何办理
一比一原版(GWU,GW毕业证)加利福尼亚大学|尔湾分校毕业证如何办理
obyzuk
 
Eco-Innovations and Firm Heterogeneity. Evidence from Italian Family and Nonf...
Eco-Innovations and Firm Heterogeneity.Evidence from Italian Family and Nonf...Eco-Innovations and Firm Heterogeneity.Evidence from Italian Family and Nonf...
Eco-Innovations and Firm Heterogeneity. Evidence from Italian Family and Nonf...
University of Calabria
 
Tumelo-deep-dive-into-pass-through-voting-Feb23 (1).pdf
Tumelo-deep-dive-into-pass-through-voting-Feb23 (1).pdfTumelo-deep-dive-into-pass-through-voting-Feb23 (1).pdf
Tumelo-deep-dive-into-pass-through-voting-Feb23 (1).pdf
Henry Tapper
 
where can I find a legit pi merchant online
where can I find a legit pi merchant onlinewhere can I find a legit pi merchant online
where can I find a legit pi merchant online
DOT TECH
 
How Non-Banking Financial Companies Empower Startups With Venture Debt Financing
How Non-Banking Financial Companies Empower Startups With Venture Debt FinancingHow Non-Banking Financial Companies Empower Startups With Venture Debt Financing
How Non-Banking Financial Companies Empower Startups With Venture Debt Financing
Vighnesh Shashtri
 
Pensions and housing - Pensions PlayPen - 4 June 2024 v3 (1).pdf
Pensions and housing - Pensions PlayPen - 4 June 2024 v3 (1).pdfPensions and housing - Pensions PlayPen - 4 June 2024 v3 (1).pdf
Pensions and housing - Pensions PlayPen - 4 June 2024 v3 (1).pdf
Henry Tapper
 
GeM ppt in railway for presentation on gem
GeM ppt in railway  for presentation on gemGeM ppt in railway  for presentation on gem
GeM ppt in railway for presentation on gem
CwierAsn
 
2. Elemental Economics - Mineral demand.pdf
2. Elemental Economics - Mineral demand.pdf2. Elemental Economics - Mineral demand.pdf
2. Elemental Economics - Mineral demand.pdf
Neal Brewster
 
5 Tips for Creating Standard Financial Reports
5 Tips for Creating Standard Financial Reports5 Tips for Creating Standard Financial Reports
5 Tips for Creating Standard Financial Reports
EasyReports
 
NEW NORMAL! WHAT BECOMES OF ACCOUNTING PROFESSION
NEW NORMAL!  WHAT BECOMES OF ACCOUNTING PROFESSION NEW NORMAL!  WHAT BECOMES OF ACCOUNTING PROFESSION
NEW NORMAL! WHAT BECOMES OF ACCOUNTING PROFESSION
Godwin Emmanuel Oyedokun MBA MSc PhD FCA FCTI FCNA CFE FFAR
 
Donald Trump Presentation and his life.pptx
Donald Trump Presentation and his life.pptxDonald Trump Presentation and his life.pptx
Donald Trump Presentation and his life.pptx
SerdarHudaykuliyew
 
Abhay Bhutada Leads Poonawalla Fincorp To Record Low NPA And Unprecedented Gr...
Abhay Bhutada Leads Poonawalla Fincorp To Record Low NPA And Unprecedented Gr...Abhay Bhutada Leads Poonawalla Fincorp To Record Low NPA And Unprecedented Gr...
Abhay Bhutada Leads Poonawalla Fincorp To Record Low NPA And Unprecedented Gr...
Vighnesh Shashtri
 
What price will pi network be listed on exchanges
What price will pi network be listed on exchangesWhat price will pi network be listed on exchanges
What price will pi network be listed on exchanges
DOT TECH
 
一比一原版(Greenwich毕业证)格林威治大学毕业证如何办理
一比一原版(Greenwich毕业证)格林威治大学毕业证如何办理一比一原版(Greenwich毕业证)格林威治大学毕业证如何办理
一比一原版(Greenwich毕业证)格林威治大学毕业证如何办理
ucyduz
 

Recently uploaded (20)

The European Unemployment Puzzle: implications from population aging
The European Unemployment Puzzle: implications from population agingThe European Unemployment Puzzle: implications from population aging
The European Unemployment Puzzle: implications from population aging
 
Scope Of Macroeconomics introduction and basic theories
Scope Of Macroeconomics introduction and basic theoriesScope Of Macroeconomics introduction and basic theories
Scope Of Macroeconomics introduction and basic theories
 
How to get verified on Coinbase Account?_.docx
How to get verified on Coinbase Account?_.docxHow to get verified on Coinbase Account?_.docx
How to get verified on Coinbase Account?_.docx
 
This assessment plan proposal is to outline a structured approach to evaluati...
This assessment plan proposal is to outline a structured approach to evaluati...This assessment plan proposal is to outline a structured approach to evaluati...
This assessment plan proposal is to outline a structured approach to evaluati...
 
when will pi network coin be available on crypto exchange.
when will pi network coin be available on crypto exchange.when will pi network coin be available on crypto exchange.
when will pi network coin be available on crypto exchange.
 
can I really make money with pi network.
can I really make money with pi network.can I really make money with pi network.
can I really make money with pi network.
 
一比一原版(GWU,GW毕业证)加利福尼亚大学|尔湾分校毕业证如何办理
一比一原版(GWU,GW毕业证)加利福尼亚大学|尔湾分校毕业证如何办理一比一原版(GWU,GW毕业证)加利福尼亚大学|尔湾分校毕业证如何办理
一比一原版(GWU,GW毕业证)加利福尼亚大学|尔湾分校毕业证如何办理
 
Eco-Innovations and Firm Heterogeneity. Evidence from Italian Family and Nonf...
Eco-Innovations and Firm Heterogeneity.Evidence from Italian Family and Nonf...Eco-Innovations and Firm Heterogeneity.Evidence from Italian Family and Nonf...
Eco-Innovations and Firm Heterogeneity. Evidence from Italian Family and Nonf...
 
Tumelo-deep-dive-into-pass-through-voting-Feb23 (1).pdf
Tumelo-deep-dive-into-pass-through-voting-Feb23 (1).pdfTumelo-deep-dive-into-pass-through-voting-Feb23 (1).pdf
Tumelo-deep-dive-into-pass-through-voting-Feb23 (1).pdf
 
where can I find a legit pi merchant online
where can I find a legit pi merchant onlinewhere can I find a legit pi merchant online
where can I find a legit pi merchant online
 
How Non-Banking Financial Companies Empower Startups With Venture Debt Financing
How Non-Banking Financial Companies Empower Startups With Venture Debt FinancingHow Non-Banking Financial Companies Empower Startups With Venture Debt Financing
How Non-Banking Financial Companies Empower Startups With Venture Debt Financing
 
Pensions and housing - Pensions PlayPen - 4 June 2024 v3 (1).pdf
Pensions and housing - Pensions PlayPen - 4 June 2024 v3 (1).pdfPensions and housing - Pensions PlayPen - 4 June 2024 v3 (1).pdf
Pensions and housing - Pensions PlayPen - 4 June 2024 v3 (1).pdf
 
GeM ppt in railway for presentation on gem
GeM ppt in railway  for presentation on gemGeM ppt in railway  for presentation on gem
GeM ppt in railway for presentation on gem
 
2. Elemental Economics - Mineral demand.pdf
2. Elemental Economics - Mineral demand.pdf2. Elemental Economics - Mineral demand.pdf
2. Elemental Economics - Mineral demand.pdf
 
5 Tips for Creating Standard Financial Reports
5 Tips for Creating Standard Financial Reports5 Tips for Creating Standard Financial Reports
5 Tips for Creating Standard Financial Reports
 
NEW NORMAL! WHAT BECOMES OF ACCOUNTING PROFESSION
NEW NORMAL!  WHAT BECOMES OF ACCOUNTING PROFESSION NEW NORMAL!  WHAT BECOMES OF ACCOUNTING PROFESSION
NEW NORMAL! WHAT BECOMES OF ACCOUNTING PROFESSION
 
Donald Trump Presentation and his life.pptx
Donald Trump Presentation and his life.pptxDonald Trump Presentation and his life.pptx
Donald Trump Presentation and his life.pptx
 
Abhay Bhutada Leads Poonawalla Fincorp To Record Low NPA And Unprecedented Gr...
Abhay Bhutada Leads Poonawalla Fincorp To Record Low NPA And Unprecedented Gr...Abhay Bhutada Leads Poonawalla Fincorp To Record Low NPA And Unprecedented Gr...
Abhay Bhutada Leads Poonawalla Fincorp To Record Low NPA And Unprecedented Gr...
 
What price will pi network be listed on exchanges
What price will pi network be listed on exchangesWhat price will pi network be listed on exchanges
What price will pi network be listed on exchanges
 
一比一原版(Greenwich毕业证)格林威治大学毕业证如何办理
一比一原版(Greenwich毕业证)格林威治大学毕业证如何办理一比一原版(Greenwich毕业证)格林威治大学毕业证如何办理
一比一原版(Greenwich毕业证)格林威治大学毕业证如何办理
 

CAGR Compound Annual Growth Rate

  • 2. Type Public limited company LSE: Traded as NYSE: Industry Pharmaceutical, biotechnology Glaxo Wellcome Predecessor(s) SmithKline Beecham Founded 2000 (London) Headquarters London, United Kingdom Chris Gent (Chairman) Key people Andrew Witty (Chief Executive) Pharmaceuticals, vaccines, oral healthcare Products products, nutritional products, over-the-counter medicines Revenue £28.392 billion (2010)[1] Net income £1.853 billion (2010)[1] Total equity £9.745 billion (2010)[2] Employees 96,500 (2010
  • 3. Compound Annual Growth Rate - CAGR  The year-over-year growth rate of an investment over a specified period of time.  Formula for CAGR [{Current value of sales/value of sales from base year]1/n -1}* 100]
  • 4. GLAXOSMITHKLINE PHARMACEUTICALS (CAGR) Year 2010 2009 2008 2007 2006 Net Sales 2,125.20 1,884.14 1,676.36 1,578.58 1,541.93 PAT 563.69 512.29 576.57 537.66 545.51 CAGR 8.35% 5.14% 2.11% 0.59% (Sales) CAGR 0.82% -1.56% 1.39% -0.36% (PAT)
  • 5. 10.00% 8.00% 6.00% 4.00% CAGR (Sales) CAGR (PAT) 2.00% 0.00% 2010 2009 2008 2007 -2.00% -4.00%
  • 6. CAGR of Industry (Sales) Year 2010 2009 2008 2007 2006 RANBAXY 5,646.37 4,781.59 4,652.04 4,293.02 4,165.12 LUPIN LTD 3,690.09 2,954.70 2,575.39 1,985.79 1,652.93 DR.REDDY'S 4,395.60 3,999.50 3,343.89 3,783.26 2,003.26 LAB Glaxos 2,125.20 1,884.14 1,676.36 1,578.58 1,541.93 mith Total 15857.26 13619.93 12247.66 11640.65 9363.24 CAGR 14.08% 9.82% 6.94% 5.59%
  • 7. CAGR of Industry (PAT) Year 2010 2009 2008 2007 2006 RANBAXY 1,148.73 571.98 -1,044.80 617.72 380.54 LUPIN LTD 648.93 416.97 443.38 302.06 182.72 DR.REDD 846.10 560.90 475.22 1,176.86 Y'S LAB 211.12 Glaxos 563.69 512.29 576.57 537.66 545.51 mith TOTAL 3207.45 2062.14 450.37 2634.3 1319.89 CAGR 24.85% 11.80% -23.57% 18.86%
  • 8. Industry Vs. Glaxosmith YEAR 2010 2009 2008 2007 Glaxosmith 8.35% 5.14% 2.11% 0.59% Industry 14.08% 9.82% 6.94% 5.59% 16.00% 14.00% 12.00% 10.00% 8.00% Glaxosmith 6.00% Industry 4.00% 2.00% 0.00% 2010 2009 2008 2007